Momenta Pharmaceuticals Inc Quick Ratio (MNTA) starting from the second quarter 2020 to second quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Momenta Pharmaceuticals inc   (NASDAQ: MNTA)

Momenta Pharmaceuticals Inc 's Quick Ratio

MNTA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Momenta Pharmaceuticals Inc 's Cash & cash equivalent, this led to improvement in Momenta Pharmaceuticals Inc 's Quick Ratio to 6.08, Quick Ratio remained below Momenta Pharmaceuticals inc average.

Within Biotechnology & Pharmaceuticals industry 63 other companies have achieved higher Quick Ratio than Momenta Pharmaceuticals Inc in second quarter 2020. While Quick Ratio total ranking has improved so far during the Q2 2020 to 611, from total ranking in the first quarter 2020 at 669.

Explain Quick Ratio?
How much Cash & cash equivalents MNTA´s has?
What are MNTA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MNTA Quick Ratio (Jun 30 2020)
Q2		 (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2
Y / Y Current Liabilities Change 71.78 % 61.22 % 41.6 % -25.46 % -15.49 %
Y / Y Cash & cash equivalent Change 61.37 % 38.17 % 100.48 % -1.22 % -13.02 %
Quick Ratio MRQ 6.08 5.57 11.61 6.7 6.48
MNTA's Total Ranking # 611 # 669 # 0 # 562 # 577
Seq. Current Liabilities Change -13.75 % 14.01 % 79.74 % -2.81 % -19.05 %
Seq. Cash & cash equivalent Change -5.81 % -45.3 % 211.65 % 0.5 % -19.36 %



Quick Ratio second quarter 2020 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 64
Healthcare Sector # 320
Overall Market # 611


Quick Ratio Statistics
High Average Low
22.83 9.87 3.56
(Dec 31 2011)   (Jun 30 2015)




Financial Statements
Momenta Pharmaceuticals Inc 's Current Liabilities $ 72 Millions Visit MNTA's Balance sheet
Momenta Pharmaceuticals Inc 's Cash & cash equivalent $ 436 Millions Visit MNTA's Balance sheet
Source of MNTA's Sales Visit MNTA's Sales by Geography


Cumulative Momenta Pharmaceuticals Inc 's Quick Ratio

MNTA's Quick Ratio for the trailling 12 Months

MNTA Quick Ratio

 (Jun 30 2020)
12 Months		 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months
Y / Y Current Liabilities TTM Growth 34.68 % 15.22 % 13.66 % 8.58 % -4.51 %
Y / Y Cash & cash equivalent TTM Growth 54.86 % 37.85 % 29.42 % -16.61 % -23.45 %
Quick Ratio TTM 7.52 7.77 8.34 7.01 6.54
Total Ranking TTM # 4156 # 4157 # 0 # 322 # 4078
Seq. Current Liabilities TTM Growth 12.57 % 15.27 % 11.56 % -6.96 % -3.7 %
Seq. Cash & cash equivalent TTM Growth 8.96 % 7.42 % 32.65 % -0.26 % -3.01 %

Quick ratio ranking by company, industry and sector >> Back to MNTA Financial Strength Comparisons >> Go to Compare MNTA Quick Ratio to its Competitors

On the trailing twelve months basis Due to fall in Current Liabilities in the Q2 2020 to $71.73 millions, cumulative Quick Ratio decreased to 7.52 above the MNTA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 114 other companies have achieved higher Quick Ratio than Momenta Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 4156, from total ranking during the twelve months ending first quarter 2020 at 4157.

Explain Quick Ratio?
How much Cash & cash equivalents MNTA´s has?
What are MNTA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 115
Healthcare Sector # 868
Within the Market # 4156


trailing twelve months Quick Ratio Statistics
High Average Low
14.78 7.06 4.03
(Dec 31 2013)   (Sep 30 2017)




Companies with similar Quick Ratio in the quarter ending Jun 30 2020, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2020 MRQ Cash & cash equivalentJun 30 2020 MRQ Current Liabilities
Forma Therapeutics Holdings Inc.  16.69 $ 414.301  Millions$ 24.818  Millions
Tectonic Therapeutic Inc   15.86 $ 244.380  Millions$ 15.411  Millions
Iovance Biotherapeutics inc   15.74 $ 771.879  Millions$ 49.032  Millions
Halozyme Therapeutics Inc   15.22 $ 385.446  Millions$ 25.325  Millions
Immunovant Inc   14.34 $ 280.279  Millions$ 19.544  Millions
Repligen Corp  13.86 $ 560.364  Millions$ 40.431  Millions
Viskase Holdings inc   13.84 $ 5.909  Millions$ 0.427  Millions
Adverum Biotechnologies Inc   13.18 $ 280.139  Millions$ 21.254  Millions
Crispr Therapeutics Ag  12.68 $ 945.068  Millions$ 74.505  Millions
Kalaris Therapeutics Inc   11.72 $ 104.451  Millions$ 8.915  Millions
Checkmate Pharmaceuticals Inc   11.50 $ 80.309  Millions$ 6.985  Millions
Opthea Limited  11.26 $ 50.596  Millions$ 4.495  Millions
Atara Biotherapeutics Inc   10.97 $ 347.712  Millions$ 31.684  Millions
Adaptimmune Therapeutics Plc  10.87 $ 418.988  Millions$ 38.559  Millions
Relay Therapeutics Inc   10.74 $ 137.053  Millions$ 12.765  Millions
Surface Oncology Inc   10.64 $ 112.539  Millions$ 10.577  Millions
Quince Therapeutics Inc   10.55 $ 144.504  Millions$ 13.693  Millions
X4 Pharmaceuticals Inc  10.54 $ 103.744  Millions$ 9.841  Millions
Acceleron Pharma inc  10.43 $ 389.810  Millions$ 37.360  Millions
Vir Biotechnology Inc   10.25 $ 563.404  Millions$ 54.940  Millions
Genetic Technologies Limited  10.17 $ 9.798  Millions$ 0.963  Millions
Twist Bioscience Corporation  9.94 $ 311.759  Millions$ 31.377  Millions
Old Ayala Inc   9.91 $ 57.355  Millions$ 5.785  Millions
Voyager Therapeutics Inc   9.72 $ 229.670  Millions$ 23.620  Millions
Jounce Therapeutics inc   9.64 $ 127.205  Millions$ 13.201  Millions
Fate Therapeutics Inc   9.56 $ 433.074  Millions$ 45.322  Millions
Denali Therapeutics Inc   9.40 $ 549.581  Millions$ 58.464  Millions
Prevail Therapeutics Inc   9.14 $ 117.523  Millions$ 12.863  Millions
Autolus Therapeutics Plc  9.07 $ 212.044  Millions$ 23.379  Millions
Editas Medicine Inc   8.79 $ 598.720  Millions$ 68.150  Millions

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.